Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for DTIL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 45.29M
March 31, 2026 76.10M
December 31, 2025 92.25M
September 30, 2025 16.63M
June 30, 2025 34.05M
March 31, 2025 49.34M
December 31, 2024 56.39M
September 30, 2024 64.87M
June 30, 2024 74.71M
March 31, 2024 37.21M
December 31, 2023 18.86M
September 30, 2023 29.06M
June 30, 2023 34.04M
March 31, 2023 40.18M
December 31, 2022 60.43M
September 30, 2022 84.38M
June 30, 2022 103.02M
March 31, 2022 69.66M
Date Value
December 31, 2021 91.17M
September 30, 2021 101.44M
June 30, 2021 100.55M
March 31, 2021 58.82M
December 31, 2020 44.42M
September 30, 2020 63.82M
June 30, 2020 85.60M
March 31, 2020 115.03M
December 31, 2019 138.31M
September 30, 2019 155.79M
June 30, 2019 173.98M
March 31, 2019 10.83M
December 31, 2018 39.96M
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017 -26.37M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Amgen, Inc. 11.69B
4D Molecular Therapeutics, Inc. 407.66M
Agenus, Inc. -199.08M
Anika Therapeutics, Inc. 137.28M
BioCryst Pharmaceuticals, Inc. -454.29M

Shareholders Equity (Quarterly) Related Metrics